SEMA MISIR^1,*, SERAP OZER YAMAN², NINA PETROVIĆ^3,4, CEREN SUMER⁵, CEYLAN HEPOKUR¹, YUKSEL ALIYAZICIOGLU²

Oncology Research, Vol.30, No.4, pp. 157-172, 2022, DOI:10.32604/or.2022.027547

Abstract Breast cancer (BC) is the most common heterogeneous disease in women and one of the leading causes of cancer-related death. Surgery, chemotherapy, radiotherapy, hormone, and targeted therapy are the gold standards for BC treatment. One of the significant challenges during the treatment of BC represents resistance to chemotherapeutics, resistance that severely limits the use and effectiveness of the drugs used for BC treatment. Therefore, it is essential to develop new strategies to improve therapeutic efficacy. Circular RNAs (circRNAs) are a large group of non-coding RNAs that covalently form closed circular loops by joining their 5′, and 3′; ends. Accumulating evidence… More >

UROS BUMBASIREVIC^1,2,*, MARKO ZIVKOVIC¹, MILOS PETROVIC¹, VESNA CORIC^2,3, NIKOLA LISICIC¹, NEBOJSA BOJANIC^1,2

Oncology Research, Vol.30, No.3, pp. 117-128, 2022, DOI:10.32604/or.2022.027511

Abstract Seminomas are most commonly diagnosed in clinical stage I (CSI). After orchiectomy, approximately 15% of patients in this stage have subclinical metastases. Adjuvant radiotherapy (ART) delivered to the retroperitoneum and ipsilateral pelvic lymph nodes has been the mainstay of treatment for many years. Although highly efficient, with long-term cancer-specific survival (CSS) rates approaching almost 100%, ART is associated with considerable long-term consequences, particularly cardiovascular toxicity and increased risk of secondary malignancies (SMN). Therefore, active surveillance (AS) and adjuvant chemotherapy (ACT) were developed as alternative treatment options. While AS prevents patient overtreatment, it is associated with strict follow-up regimens and increased… More >

YUNG-SUNG YEH^1,2,3, HSIANG-LIN TSAI^4,5, YEN-CHENG CHEN^4,6, WEI-CHIH SU^4,6, PO-JUNG CHEN^4,6, TSUNG-KUN CHANG^4,6,7, CHING-CHUN LI⁴, CHING-WEN HUANG^4,5, JAW-YUAN WANG^{4,5,6,8,9,10,*}

Oncology Research, Vol.30, No.2, pp. 65-76, 2022, DOI:10.32604/or.2022.026659

Abstract The controversial outcomes in patients with metastatic colorectal cancer (mCRC) highlight the need for developing effective systemic neoadjuvant treatment strategies to improve clinical results. The optimal treatment cycles in patients with mCRC for metastasectomy remain undefined. This retrospective study compared the efficacy, safety, and survival of cycles of neoadjuvant chemotherapy/targeted therapy for such patients. Sixty-four patients with mCRC who received neoadjuvant chemotherapy/targeted therapy following metastasectomy were enrolled between January 2018 and April 2022. Twenty-eight patients received 6 cycles of chemotherapy/targeted therapy, whereas 36 patients received ≥7 cycles (median, 13; range, 7–20). Clinical outcomes, including response, progression-free survival (PFS), overall survival… More >

Huihui Zhang, Jing Yan, Xiaoyong Ren, Ying Sheng, Zhenghui Wang, Jianmin Liang, Yan Yan, Yangyang Jia, Zhihui Li, Jin Hou^*

Oncologie, Vol.24, No.4, pp. 707-716, 2022, DOI:10.32604/oncologie.2022.027023

Abstract Objective: To assess the efficacy and toxicity of nimotuzumab combined with neoadjuvant or induction chemotherapy for head and neck squamous cell carcinoma (HNSCC). Methods: Patients received intravenous nimotuzumab (400 mg, weekly for 1–3 weeks) combined with chemotherapy (5-fluorouracil/paclitaxel/docetaxel + nedaplatin/cisplatin for 1–2 cycles), prior to definitive surgical resection, radiotherapy or other treatments. The primary endpoint was the objective response rate (ORR). The secondary endpoints were tumor downstaging, complete response rate (CRR), partial response rate (PRR), disease control rate (DCR), R0 resection rate, pathological complete response (pCR), larynx preservation rate, overall survival (OS), progression-free survival (PFS), and safety. Results: A total… More >

Grégory Ninot^1,2,*, Estelle Guerdoux^1,2, François Carbonnel¹, Kerstin Faravel², Ludovic Ismael¹, Fanny Leenhardt², Béatrice Lognos¹, Caroline Perrier², Laurent Philibert², Boris Tronc¹, Marie Viala²

Oncologie, Vol.24, No.4, pp. 605-612, 2022, DOI:10.32604/oncologie.2022.024558

Abstract A retrospective observational study carried out in the United States showed a decrease in survival in patients treated for breast, prostate, lung and colorectal cancer with complementary medicines. We verified this result with a French population of consecutive 636 patients diagnosed with the same cancer and treated with oral chemotherapy in an hospital for three years. An interview by a pharmacist before the administration of oral chemotherapy was made to identify the complementary medicines used by the patients. We compared the overall survival using a log-rank test by stratifying the groups (number of cancers, number of comorbidities, age, sex). The… More >

ZAHRA NASRPOUR NAVAEI¹, GHAZALEH KHALILI-TANHA¹, AMIR SADRA ZANGOUEI², MOHAMMAD REZA ABBASZADEGAN³, MEYSAM MOGHBELI^1,3,*

Oncology Research, Vol.29, No.4, pp. 235-250, 2021, DOI:10.32604/or.2022.025323

Abstract Chemotherapy is one of the main therapeutic modalities for cancer patients. Cisplatin (CDDP), as one of the first-line drugs, is of great importance in the chemotherapy of various tumors. However, a significant percentage of cancer patients are resistant to CDDP treatment. Due to the CDDP side effects on normal tissues, the diagnosis of CDDP resistance is required to suggest the most efficient therapeutic strategies for cancer patients. Several molecular mechanisms and signaling pathways are associated with CDDP response. The PI3K/AKT signaling pathway has a pivotal role in the transmission of extracellular signals into the cells to regulate various pathophysiological processes… More >

Haojie Zhang¹, Xiaohong Wang^2,*, Yue Yu², Zhenlin Yang^3,*

Oncologie, Vol.24, No.2, pp. 247-259, 2022, DOI:10.32604/oncologie.2022.020993

Abstract Chemotherapy plays an important role in controlling cancer progression, but the long-term use of chemotherapeutic agents can lead to drug resistance and eventually treatment failure. Therefore, elucidation of the mechanism of drug resistance is the key to solve the problem of chemotherapy resistance. In recent years, exosomes derived from tumor cells have received extensive attention from researchers. In this paper, we reviewed the role and mechanism of exosome-mediated tumor drug resistance in recent years, summarized the related studies of exosome and chemotherapy drug resistance, and focused on several different ways by which exosomes participate in tumor drug resistance. It includes… More >

Yuanshan Yao, Yinjie Zhou, Zhenhua Yang, Hongbo Huang, Haibo Shen

Oncology Research, Vol.27, No.2, pp. 203-210, 2019, DOI:10.3727/096504018X15202953107093

Abstract The purpose of this study was to determine the effects of resection coupled with standard chemotherapy on the survival prognosis of patients with early stage small cell lung carcinoma (SCLC). Patients (n=110) with mediastinal lymph node-negative SCLC were enrolled in this study. The baseline clinical data of patients with surgery were retrospectively reviewed. Overall survival (OS) and progression-free survival (PFS) were measured by Kaplan–Meier and log-rank test analyses. Ninety-eight patients received mediastinoscopy biopsy, and pulmonary lobectomy or sublobar resection, and 67 patients underwent adjuvant chemotherapy after pulmonary lobectomy. Adjuvant chemotherapy after surgical intervention was associated with longer OS (median OS:… More >

Jing Tang^*1, Xu Yong Li^†1, Jing Bo Liang^‡, De Wu^§, Li Peng^¶, Xiaobing Li^¶

Oncology Research, Vol.27, No.6, pp. 635-641, 2019, DOI:10.3727/096504018X15288447760357

Abstract Apatinib is an oral TKI with antiangiogenic properties, and it is currently approved for the treatment of advanced gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell lung cancer (NSCLC). Since the combination of chemotherapy and an antiangiogenic agent has been shown to be a feasible strategy in NSCLC, it is conceivable that a similar approach combining apatinib with chemotherapy may yield clinical activity. With this in mind, we investigated the efficiency of apatinib in combination with pemetrexed or docetaxel in advanced NSCLC. We treated a total of 20 patients with… More >

Takashi Saito^*†, Atsuo Okamura^‡, Junichiro Inoue^†, Daisuke Makiura^†, Hisayo Doi^§, Kimikazu Yakushijin^¶, Hiroshi Matsuoka^¶, Yoshitada Sakai^†#, Rei Ono^*

Oncology Research, Vol.27, No.4, pp. 469-474, 2019, DOI:10.3727/096504018X15267574931782

Abstract Chemotherapy-induced peripheral neuropathy (CIPN) frequently occurs in lymphoma patients receiving R-CHOP, a drug combination therapy. Although severe CIPN may lead to reduction and/or discontinuation of the medication, predictive factors of CIPN have not been investigated sufficiently to date. We performed a retrospective exploratory research to determine associations between prevalence of severe CIPN and sociodemographic data, health characteristics, and medical conditions such as anemia at initial diagnosis. Forty patients (indolent lymphoma, n=9; diffuse large B-cell lymphoma; n=31) received R-CHOP therapy from September 2009 to July 2014. The median age of patients was 58 years (range=27–76 years). Statistical analyses were applied to… More >